Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis
- 19 March 2024
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1888-1893
Abstract
Summary: Over 50% of patients with systemic LCH are not cured with front‐line therapies, and data to guide salvage options are limited. We describe 58 patients with LCH who were treated with clofarabine. Clofarabine monotherapy was active against LCH in this cohort, including heavily pretreated patients with a systemic objective response rate of 92.6%, higher in children (93.8%) than adults (83.3%). BRAFV600E+ variant allele frequency in peripheral blood is correlated with clinical responses. Prospective multicentre trials are warranted to determine optimal dosing, long‐term efficacy, late toxicities, relative cost and patient‐reported outcomes of clofarabine compared to alternative LCH salvage therapy strategies.Keywords
Funding Information
- National Institutes of Health (CA154947)
- St. Baldrick's Foundation
- Leukemia and Lymphoma Society
This publication has 20 references indexed in Scilit:
- Efficacy of MEK inhibition in patients with histiocytic neoplasmsNature, 2019
- Langerhans-Cell HistiocytosisNew England Journal of Medicine, 2018
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell HistiocytosisJAMA Oncology, 2018
- Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistasPediatric Blood & Cancer, 2017
- BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groupsJournal of Experimental Medicine, 2014
- Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman diseasePediatric Blood & Cancer, 2013
- Clofarabine salvage therapy for refractory high‐risk langerhans cell histiocytosisPediatric Blood & Cancer, 2012
- 2′‐chlorodeoxyadenosine (2‐CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH‐S‐98 protocol of the histiocyte societyPediatric Blood & Cancer, 2009
- Clofarabine in refractory Langerhans cell histiocytosisPediatric Blood & Cancer, 2008
- Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study GroupPediatric Blood & Cancer, 2004